ClinicalTrials.gg
Drug

Cadonilimab clinical trials

Also written AK104.

studies test it
173
open now
113
in phase 3
19
first study started
2017

How each study uses cadonilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the cadonilimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Cadonilimab
68
Cadonilimab Injection
8
Cadonilimab (AK104)
8
Candonilimab
3
AK104 - Chemotherapy
2

Development codes

AK104
75

In one entry with another drug

Given together, or one or the other

Cadonilimab+regorafenib
2
AK104+anlotinib
2

Studies by the year they started

172 studies that test it; most in 2023 (61); 1 more planned to start later

Studies that test cadonilimab, by start year
YearStudies
20171
20192
20209
20216
202218
202361
202449
202515
202611

Who runs them

Industry 45 · Other 128

Akeso (40) · Sun Yat-sen University (10) · Tianjin Medical University Cancer Institute and Hospital (8) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (6) · Fudan University (4) · West China Hospital (3) · Sichuan University (3) · The First Affiliated Hospital of Zhengzhou University (3)

Often tested with

Tested in the same studies.

Anlotinib (10) · Ivonescimab (8) · Lenvatinib (6) · Disitamab vedotin (5) · Paclitaxel (4) · Albumin-Bound Paclitaxel (2) · Docetaxel (2) · Dresbuxelimab (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 29, 5 in phase 3

Studies that test cadonilimab, phase 3 first.

Studies

Open first, then newest update. How each study uses cadonilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 173

See all 173 studies that test cadonilimab →

Given beside what is tested · 16 — cadonilimab is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with cadonilimab

Codes

What other systems call cadonilimab · ClinicalTrials.gg INT015265

  • UNII (FDA) 6FYG1DS4NWCADONILIMABOne source FDA
  • NCI Thesaurus C153379CadonilimabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.